Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000917341 | SCV001062616 | likely benign | not provided | 2022-10-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004029409 | SCV004957105 | uncertain significance | Inborn genetic diseases | 2023-11-14 | criteria provided, single submitter | clinical testing | The c.1482G>T (p.E494D) alteration is located in exon 12 (coding exon 11) of the SPTBN2 gene. This alteration results from a G to T substitution at nucleotide position 1482, causing the glutamic acid (E) at amino acid position 494 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004702520 | SCV005203091 | uncertain significance | not specified | 2024-07-09 | criteria provided, single submitter | clinical testing | Variant summary: SPTBN2 c.1482G>T (p.Glu494Asp) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.6e-05 in 242396 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in SPTBN2 causing Spinocerebellar Ataxia 5, allowing no conclusion about variant significance. To our knowledge, no occurrence of c.1482G>T in individuals affected with Spinocerebellar Ataxia 5 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 741207). Based on the evidence outlined above, the variant was classified as uncertain significance. |